Pipeline

Wholly-owned Collaboration
Product (Partner)
Phase
Binimetinib / MEK162* Indication: Cancer
Target: MEK
   Phase 3
Encorafenib / LGX818* Indication: Cancer
Target: BRAF
   Phase 3
Selumetinib (AstraZeneca) Indication: Cancer
Target: MEK
   Phase 3
Filanesib / ARRY-520 Indication: Multiple Myeloma
Target: KSP
  Phase 2
ARRY-797 Indication: LMNA-related DCM
Target: p38
  Phase 2
ARRY-502 Indication: Asthma
Target: CRTh2
  Phase 2
Ipatasertib / GDC-0068 (Genentech) Indication: Cancer
Target: AKT
  Phase 2
Motolimod / VTX2337 (VentiRx / Celgene) Indication: Cancer
Target: TLR
  Phase 2
Varlitinib / ASLAN001 (ASLAN) Indication: Cancer
Target: Pan-HER
  Phase 2
Danoprevir (Roche) Indication: Hepatitis C
Target: NS3 Protease
  Phase 2
LY2606368 (Eli Lilly) Indication: Cancer
Target: Chk-1
  Phase 2
LOXO-101 (Loxo Oncology) Indication: Cancer
Target: PanTrk
  Phase 2
ONT-380 (Oncothyreon) Indication: Breast Cancer
Target: HER-2
  Phase 2
ARRY-382 Indication: Cancer
Target: CSF1R
 Phase 1
ARRY-614 Indication: MDS
Target: p38/Tie2
 Phase 1
GDC-0575 (Genentech) Indication: Cancer
Target: Chk-1
 Phase 1
GDC-0994 (Genentech) Indication: Cancer
Target: ERK
 Phase 1

*Wholly owned in the United States, Canada, Japan, Korea and Israel